Imaging calcium deposits in dermatomyositis patients
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study uses a special imaging technique (photoacoustic/ultrasound) to look at calcium deposits under the skin in people with dermatomyositis. It aims to find patterns that help doctors understand the condition and track how well treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with dermatomyositis, a type of inflammatory muscle disease.
- You have a condition called calcinosis cutis — calcium deposits that form hard lumps under your skin.
- You do not have another connective tissue disease or inclusion body myositis (IBM).
- Your diagnosis of dermatomyositis was confirmed by standard medical criteria (EULAR/ACR 2017 rules).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
This study looks at how well skin symptoms improve in adults with cutaneous dermatomyositis by using a specific skin-scoring tool. The results may help doctors better measure treatment response and guide care.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
This trial looks at a type of skin inflammation called panniculitis that can happen in people with dermatomyositis. The goal is to learn more about this condition so that better treatments can be developed.
This study looks at how severe dermatomyositis is in people who develop it as children or adults. It aims to better understand the disease and may help guide future treatments.
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.